The efficacy of the calcium-channel blocker nicardipine in the treatment of Raynaud's phenomenon was assessed in a prospective, double-blind, randomized, crossover trial in 20 patients. Each patient received nicardipine 20 mg or placebo three times a day for two weeks and then was crossed over for two weeks. Nicardipine significantly decreased the frequency and severity of Raynaud's phenomenon as compared with placebo. The authors conclude that nicardipine is effective in the treatment of Raynaud's phenomenon.
Get full access to this article
View all access options for this article.
References
1.
Anonymous editorial. Episodic digital vasospasm—the legacy of Maurice Raynaud. Lancet1:1039-1040, 1977.
Coffman JD: Vasodilator drugs in peripheral vascular disease. N Engl J Med300:713-717, 1979.
4.
Kahan A., Weber S., Amor B., et al: Etude contrôlée de la nifédipine dans le traitement du phénomène de Raynaud. Rev Rhum Mal Ostéoartic49:337-343, 1982.
5.
Kahan A., Amor B., Menkès CJ: A randomized double-blind trial of diltiazem in the treatment of Raynaud's phenomenon. Ann Rheum Dis44:30-33, 1985.
6.
Smith CD, McKendry Rjr: Controlled trial of nifedipine in the treatment of Raynaud's phenomenon . Lancet2:1299-1301, 1982 .
7.
Rodeheffer RJ , Rommer JA, Wigley F., Smith CR: Controlled double-blind trial of nifedipine in the treatment of Raynaud's phenomenon. N Engl J Med308:880-883, 1983.
8.
Corbin Doc, Wood DA, Macintyre Cca, Housley E.: A randomized double-blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon. Eur Heart J7:165-170, 1986.
9.
Winston EL, Pariser KM, Miller KB, et al: Nifedipine as a therapeutic modality for Raynaud's phenomenon . Arthritis Rheum26:1177-1180, 1983 .
10.
Sauza J., Kraus A., Gonzalez-Amaro R., Alarcon-Segovia D.: Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double-blind trial. J Rheumatol11:362-364, 1984.
11.
Vayssairat M., Capron L., Fiessinger JN, et al: Calcium channel blockers and Raynaud's disease. Ann Intern Med95:243, 1981.
12.
Rhedda A., McCans J., Willan AR, Ford PM: A double-blind placebo-controlled crossover randomized trial of diltiazem in Raynaud's phenomenon. J Rheumatol12:724-727, 1985.
13.
Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee : Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum23:581-590, 1980.
14.
Bennett PH, Burch TA: New York Symposium on population studies in the rheumatic diseases: New diagnostic criteria. Bull Rheum Dis 17:453-458, 1967.
15.
Dixon WJ: BMDP statistical software. Berkeley, Calif., University of California Press, 1981.
16.
Zelis R.: Mechanisms of vasodilation. Am J Med74 (suppl 27 June):3-12, 1983.
17.
Stone PH, Antman EM, Muller JE, Braunwald E.: Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications. Ann Intern Med93:886-904, 1980.
18.
Braunwald E. : Mechanism of action of calcium-channel blocking agents. N Engl J Med307:1618-1627, 1982 .
19.
Kinney EL, Nicholas GG, Gallo J., et al: The treatment of severe Raynaud's phenomenon with verapamil . J Clin Pharmacol22:74-76, 1982.
20.
Seaman J., Lovy M., MacCarter D., Steigerwald J.: Verapamil in the treatment of secondary Raynaud's phenomenon. Arthritis Rheum26 (suppl):S27 (abstract), 1983.
21.
Hof RF: Calcium antagonist and the peripheral circulation: Differences and similarities between PY 108-068, nicardipine, verapamil and diltiazem. Br J Pharmacol78:375-394, 1983.
22.
Thuillez C. , Guerret M., Duhaze P., et al: Nicardipine: Pharmacokinetics and effects on carotid and brachial blood flows in normal volunteers. Br J Clin Pharmacol18:837-847, 1984.
23.
Rodnan GP, Myerowitz RL, Justh GO: Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. Medicine59:393-408, 1980.
24.
McGrath MA, Peek R., Penny R.: Blood hyperviscosity with reduced skin blood flow in scleroderma. Ann Rheum Dis36:569-574, 1977.
25.
Van derMeulen J., Wouda AA, Mandema E., The TH: Immune complexes in peripheral blood polymorphonuclear leucocytes of patients with Raynaud's phenomenon. Clin Exp Immunol35:62-66, 1979.
